RxDoctor Payments Data

Caitlin Saint Aubin, MD

Obstetrics & Gynecology · Providence, RINPI 1285834119

Payments from drug & device makers

What this record shows

28 manufacturers reported payments, led by AbbVie at 55.0% of the total. Reporting peaked in 2023 at $2,313 and has fallen 70.5% since, to $683 in 2025. Among obstetrics & gynecology clinicians in RI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$5,020in general payments, 2019–2025

Across 125 payments — averaging $40.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Exeltis, USA Inc.$505
  • Sage Therapeutics, LLC$254
  • Myovant Sciences Inc.$200
  • Bayer$159
  • Coopersurgical, Inc.$140
  • plus $1K from 22 others

What the payments were for

  • Speaking & faculty fees$2,50050%
  • Food & beverage$2,52050%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,020 in reported general payments places this provider in the 90th percentile of 139 obstetrics & gynecology providers in Rhode Island.

See all obstetrics & gynecology providers in Rhode Island

Medicare billing

Part B allowed, 2024
$7,318
Medicare patients
35
Services billed
57

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Estradiol22$893
ValacyclovirValacyclovir Hcl20$273
NyliaNorethindrone-Ethin. Estradiol11$45

Paid to pharmacies, not to this prescriber.

Other obstetrics & gynecology in Providence

See the full list for Rhode Island

Where these figures come from

Is this you, or does something look wrong? →